FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely rheumatology, and can be used in the treatment of the systemic form of adult Still’s disease (ASD). To do this, colchicine is prescribed at a dose of 0.5 mg 2 times a day, with the possibility of increasing the dose to 3 mg per day. After achieving stable remission, taking a dose of 0.5 mg of colchicine 2 times a day or a titrated dose for 6 months continues with a further reduction in the dose of 0.25 mg per month until complete withdrawal of colchicine.
EFFECT: method makes it possible to increase the effectiveness of treatment of the systemic form of ASD and improve the quality of life of patients due to the combination of techniques of the claimed invention.
1 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTION OF POSTPERICARDIOTOMY SYNDROME IN PATIENTS WITH ISCHEMIC HEART DISEASE AFTER CORONARY BYPASS SURGERY | 2014 |
|
RU2556198C1 |
| METHOD FOR THE TREATMENT OF THROMBOCYTOPENIA IN CORONAVIRUS INFECTION | 2022 |
|
RU2783888C1 |
| METHOD OF TREATMENT OF AUTOIMMUNE GENERAL DISEASES AND MEDICAL PRODUCT | 2007 |
|
RU2361588C2 |
| METHOD FOR TREATMENT OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN ASSOCIATED WITH SARS-CoV-2 | 2021 |
|
RU2780939C1 |
| METHOD FOR TREATMENT OF NEW CORONAVIRUS INFECTION | 2022 |
|
RU2790939C1 |
| METHOD OF TREATING PATIENTS WITH RADIATION EXUDATIVE PERICARDITIS | 2009 |
|
RU2415667C1 |
| METHOD FOR TREATING PATIENTS WITH HIV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES WITH MODERATE AND SEVERE COVID-19 | 2022 |
|
RU2793414C1 |
| METHOD FOR DETERMINING INDICATIONS TO BEGINNING OF RECEPTION OF GENETIC ENGINEERING BIOLOGICAL PREPARATIONS WITH INEFFECTIVENESS OF BASIC ANTI-INFLAMMATORY PREPARATIONS IN EARLY FORMS OF PSORIATIC ARTHRITIS | 2020 |
|
RU2731807C1 |
| DIAGNOSTIC METHOD OF ATYPICAL CASES OF FAMILIAL MEDITERRANEAN FEVER | 2020 |
|
RU2739411C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF YERSINIOSIS IN CHILDREN | 2010 |
|
RU2422828C1 |
